The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study

European Journal of Cancer

Volumn 45, Issue 18, 2009, Pages 3198-3204

  Rosendahl, Mikkel ^a   Ahlgren, Johan ^b   Andersen, Jørn ^c   Bergh, Jonas ^d   Blomquist, Carl ^e,f   Lidbrink, Elisabet ^d   Lindman, Henrik ^e   Mouridsen, Henning ^a,g   Bjerre, Karsten ^g   Andersson, Michael ^a  

^a Rigshospitalet   (Denmark)

^b GÄVLE HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF HELSINKI   (Finland)

^g Danish Breast Cancer Cooperative Group   (Denmark)

Author keywords

Amenorrhoea; Breast cancer; Menopause; Ovarian failure

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; AGE DISTRIBUTION; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; EARLY CANCER; FEMALE; HUMAN; INDIVIDUALITY; LEUKOPENIA; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AMENORRHEA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; MENSTRUAL CYCLE; MIDDLE AGED; OVARIAN FAILURE, PREMATURE;

EID: 70450210840     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.09.019     Document Type: Article

References (33)

1. Walshe J.M., Denduluri N., and Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 24 36 (2006) 5769-5779
2. Early Breast Cancer Trialists' Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
3. Faddy M.J. Follicle dynamics during ovarian ageing. Mol Cell Endocrinol 163 1-2 (2000) 43-48
4. Anders C., Marcom P.K., Peterson B., et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26 3 (2008) 286-295
5. Meirow D., Assad G., Dor J., and Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 19 6 (2004) 1294-1299
6. Yuce M.A., Balkanli K.P., Gucer F., et al. Prevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: a dose-dependent relationship?. Eur J Gynaecol Oncol 25 5 (2004) 628-631
7. Meirow D., and Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7 6 (2001) 535-543
8. Petrek J.A., Naughton M.J., Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24 7 (2006) 1045-1051
9. Saarto T., Blomqvist C., Rissanen P., Auvinen A., and Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75 2 (1997) 301-305
10. Poikonen P., Saarto T., Lundin J., Joensuu H., and Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80 11 (1999) 1763-1766
11. Colleoni M., Price K., Castiglione-Gertsch M., et al. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 34 11 (1998) 1693-1700
12. Mayers C., Panzarella T., and Tannock I.F. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 91 12 (2001) 2246-2257
13. Cameron D.A., Massie C., Kerr G., and Leonard R.C. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89 10 (2003) 1837-1842
14. Wilking N., Lidbrink E., Wiklund T., et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18 4 (2007) 694-700
15. Jakobsen P., Bastholt L., Dalmark M., et al. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 28 6 (1991) 465-469
16. Sandstrom M., Freijs A., Larsson R., et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 14 5 (1996) 1581-1588
17. van Schaik R.H. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 23 6 (2005) 513-522
18. van Schaik R.H. Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents. Ther Drug Monit 26 2 (2004) 236-240
19. Moore M.J. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20 3 (1991) 194-208
20. Innocenti F., and Ratain M.J. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer 38 5 (2002) 639-644
21. Singh G., Saxena N., Aggarwal A., and Misra R. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 34 4 (2007) 731-733
22. Takada K., Arefayene M., Desta Z., et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50 7 (2004) 2202-2210
23. Edlund P, Gunnarsdottir K, Anderson H, et al. Side effects in treatment with FEC (5-fluorouracil, epirubicin and cyklophosphamide) in standard doses compared to tailored doses, based on hematological toxicity, for primary breast cancer. Results from the Scandinavian Breast Group 2000-1 Study. San Antoni Breast Cancer Symposium, poster no. 2057; 2005.
24. Del M.L., Venturini M., Sertoli M.R., and Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 43 2 (1997) 183-190
25. Pagani O., O'Neill A., Castiglione M., et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34 5 (1998) 632-640
26. Vanhuyse M., Fournier C., and Bonneterre J. Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol 16 8 (2005) 1283-1288
27. Parulekar W.R., Day A.G., Ottaway J.A., et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA5. J Clin Oncol 23 25 (2005) 6002-6008
28. Minton S.E., and Munster P.N. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 9 6 (2002) 466-472
29. Berliere M., Dalenc F., Malingret N., et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 8 1 (2008) 56
30. Partridge A., Gelber S., Gelber R.D., et al. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 43 11 (2007) 1646-1653
31. Andersen C.Y., Rosendahl M., Byskov A.G., et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod 23 10 (2008) 2266-2272
32. Donnez J., Martinez-Madrid B., Jadoul P., et al. Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update 12 5 (2006) 519-535
33. Oktay K., Buyuk E., Davis O., et al. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 18 1 (2003) 90-95